Eli Lilly and Company (NYSE: LLY) acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE